Menu

Medical

Sequenta Launches New Online Results Portal for Physicians

,

Secure, real-time access to ClonoSIGHT™ test results, order status, patient MRD trends SOUTH SAN FRANCISCO, Calif. DECEMBER 4, 2014 – Sequenta, Inc. today announced the launch of its new physician portal, the ClonoSIGHT Secure Portal (https://results.clonosight.com). The HIPAA-compliant online portal enables physicians to more effectively integrate the ClonoSIGHT process, an ultra-sensitive, next-generation sequencing-based technology for […]

NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England

,

Final Evaluation Determination Confirms that Soliris is a “Very Effective Treatment for aHUS with Significant Value to Patients” Final Evaluation Determination Includes the Same Conditions Discussed in Draft Recommendation, Including Establishment of an Expert Center and a Robust System to Monitor Patients Receiving Treatment CHESHIRE, Conn. November 27, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today […]

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

, ,

Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo Three Pivotal Studies Form the Basis for Global Regulatory Filings, Planned In 2015 THOUSAND OAKS, Calif. and LONDON, Nov. 25, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab […]

Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optical

,

CHESHIRE, Conn. November 25, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder. In patients with NMO, chronic, uncontrolled complement activation results in severe […]

Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer

, ,

THOUSAND OAKS, Calif., Nov. 24, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies. Amgen’s decision is based on a planned safety review by the RILOMET-1 independent data monitoring committee that found an increase in the […]

93 percent of post-survey participants reported better understanding between financial and physical health

,

November 20, 2014 — Research outlining the impact physical wellness has on financial well-being was unveiled last week at the Filene Research Institute’s “big. bright. minds.” 2014 conference. Working with hubbub health® and TwinStar Credit Union, a group of credit union executives in Filene’s i3 program launched a pilot program that demonstrated the relationship between […]

GE Healthcare Announces Omnyx™ Digital Pathology Collaboration with Caradigm

, , ,

GE Healthcare to offer Caradigm’s Identity and Access Management suite with Omnyx digital pathology solutions to streamline pathology workflows. PITTSBURGH, PA – November 19, 2014 – GE Healthcare, a leader in technology innovation, today announced it will resell Caradigm’s Single Sign-On and Context Management solutions in the United States, Canada, and specific EU countries to […]

Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients

, , ,

Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 WHITEHOUSE STATION, N.J., November 3, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation […]

Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels

, ,

Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent Amgen to Webcast Investor Call at AHA Scientific Sessions 2014 THOUSAND OAKS, Calif., Nov. 18, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational […]

European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

, , ,

Once-Daily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 18, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first […]

«‹ 22 23 24 25›»